Pixium ranked #7 of the top 100 most innovative start-ups in France by Forbes (and ranked #1 Life Science company on the list).
Biotech firm Pixium Vision, which created the device, has trialled the bionic eye in five people in France who have age-related macular degeneration.
The company has recently received positive data from the first
feasibility trial of Prima System in age-related macular degeneration
patients – most of the patients could identify letters and some
sequences of letters.
One year after the Prima device was implanted, all five patients in the Paris-based Prima-FS trial
had light perception in the central retinal area, none had had central
visual activity at enrollment, meeting the study’s primary endpoint.
Most of the patients could identify letters, and some sequences of
SMALL CAP EVENT 2019: CEO of Pixium Vision guest of La Bourse Et La Vie: “We have shown that we have exceeded our initial expectations”
A decade ago, clinicians had nothing to offer most people affected by retinal degeneration. Breakthroughs in genetics, bionics and stem-cell therapy are changing that.
#LetsgoFrance 2019 Trophy “France that shines internationally”: Pixium Vision
Scientific research and high technology now allow the blind and partially sighted to recover some of their lost sense.